PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials

REFERENCES

1. 1.↵
   1. Orbai AM,
   2. de Wit M,
   3. Mease P,
   4. Shea JA,
   5. Gossec L,
   6. Leung YY,
   7. et al.

   International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 2017;76:673–80.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Orbai AM,
   2. de Wit M,
   3. Mease PJ,
   4. Callis Duffin K,
   5. Elmamoun M,
   6. Tillett W,
   7. et al.

   Updating the Psoriatic Arthritis (PsA) Core Domain Set: a report from the PsA workshop at OMERACT 2016. J Rheumatol 2017;44:1522–8.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Boers M,
   2. Kirwan JR,
   3. Tugwell P,
   4. Beaton D,
   5. Bingham CO III,
   6. Conaghan PG,
   7. et al

   . The OMERACT handbook. [Internet. Accessed November 6, 2018.] Available from: https://omeract.org/resources
4. 4.↵
   1. Boers M,
   2. Kirwan JR,
   3. Wells G,
   4. Beaton D,
   5. Gossec L,
   6. d’Agostino MA,
   7. et al.

   Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745–53.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Højgaard P,
   2. Klokker L,
   3. Orbai AM,
   4. Holmsted K,
   5. Bartels EM,
   6. Leung YY,
   7. et al.

   A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative. Semin Arthritis Rheum 2018;47:654–5.

   OpenUrl
6. 6.↵
   1. Gossec L,
   2. de Wit M,
   3. Kiltz U,
   4. Braun J,
   5. Kalyoncu U,
   6. Scrivo R,
   7. et al;
   8. EULAR PsAID Taskforce

   . A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   EULAR RAID and PsAID questionnaires. [Internet. Accessed November 6, 2018] Available from: http://pitie-salpetriere.aphp.fr/psaid/raid_psaid_quest_home.php
8. 8.↵
   1. Tillett W,
   2. Orbai AM,
   3. Ogdie A,
   4. Leung YY,
   5. Strand V,
   6. Gladman DD,
   7. et al;
   8. GRAPPA OMERACT Psoriatic Arthritis working group

   . GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. Ann Rheum Dis 2018;77:e23.

   OpenUrlFREE Full Text
9. 9.↵
   1. Holland R,
   2. Højgaard P,
   3. Shea B,
   4. Beaton D,
   5. Tugwell P,
   6. de Wit M,
   7. et al.

   FRI0674 applicability of the PSAID12 questionnaire as a core outcome measure in PsA clinical trials: an evaluation using OMERACT Filter 2.1 instrument selection criteria. Ann Rheum Dis 2018;77:857.

   OpenUrl
10. 10.↵
    1. Holland R,
    2. Tillett W,
    3. Korendowych E,
    4. Cavill C,
    5. Waldron N,
    6. Brooke M,
    7. et al.

    Validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis 2018;77:343–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Holland R,
    2. Tillett W,
    3. Ogdie A,
    4. Leung YY,
    5. Gladman DD,
    6. Callis Duffin K,
    7. et al.

    Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: the PsA OMERACT core set workshop at the GRAPPA 2017 Annual Meeting. J Rheumatol 2018;94:17–25.

    OpenUrl
12. 12.↵
    1. de Wit M,
    2. Kvien TK,
    3. Gossec L

    . Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open 2015;1:e000129.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Salaffi F,
    2. Di Carlo M,
    3. Carotti M,
    4. Farah S,
    5. Gutierrez M

    . The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version. Ther Clin Risk Manag 2016;12:631–42.

    OpenUrl
14. 14.↵
    1. Di Carlo M,
    2. Becciolini A,
    3. Lato V,
    4. Crotti C,
    5. Favalli EG,
    6. Salaffi F

    . The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 2017;44:279–85.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Queiro R,
    2. Cañete JD,
    3. Montilla C,
    4. Abad M,
    5. Montoro M,
    6. Gómez S,
    7. et al.

    Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Res Ther 2017;19:72.

    OpenUrl
16. 16.↵
    1. Gorlier C,
    2. Orbai A,
    3. Puyraimond-Zemmour D,
    4. Coates LC,
    5. Kiltz U,
    6. Leung YY,
    7. et al.

    Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Ann Rheum Dis 2018 Nov 15 (E-pub ahead of print).
17. 17.↵
    1. Gorlier C,
    2. Puyraimond-Zemmour D,
    3. Orbai AM,
    4. Coates LC,
    5. Kiltz U,
    6. Leung YY,
    7. et al.

    Defining cutoffs corresponding to low levels of disease activity in psoriatic arthritis, using the patient-reported psoriatic arthritis impact of disease questionnaire (PsAID12): an analysis of 436 patients [abstract]. Arthritis Rheumatol 2018;70 Suppl 10:965.

    OpenUrl
18. 18.↵
    1. Orbai AM,
    2. Ogdie A

    . Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin North Am 2016;42:265–83.

    OpenUrl